Evidence map›Paper›PMID 42026560›Full record

ArticleBMC cancer2026

Re-evaluating previous dose and allowing increasing recovery (REPAIR): study protocol for a thoracic reirradiation phase I dose escalation trial.

Donna H Murrell, Nicolaus Andratschke, Alanah M Bergman, Kristy Brock, Emma M Dunne, Mitchell Liu, Aliaksandr Karotki, Alexander V Louie, Andrew Warner, Jason Vickress and 2 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06558175 (A Safety and Efficacy Trial of Reirradiation Dose Escalation in Thoracic Cancers), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06558175 phase1not yet recruitingnot on this map

A Safety and Efficacy Trial of Reirradiation Dose Escalation in Thoracic Cancers: Re-evaluating Previous Dose and Allowing Increasing Recovery (REPAIR)

TypeinterventionalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2024 to 2027Enrolled48ConditionsThoracic Cancer, Lung Cancer, Esophageal CancerArmsstereotactic body radiation therapy (SBRT)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Donna H MurrellDepartment of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. Donna.murrell@lhsc.on.ca.
Nicolaus AndratschkeUniversity Hospital of Zurich, University Hospital Zurich, Zurich, Switzerland.
Alanah M BergmanBC Cancer - Vancouver, Vancouver, BC, Canada.
Kristy BrockThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Emma M DunneBC Cancer - Vancouver, Vancouver, BC, Canada.
Mitchell LiuBC Cancer - Vancouver, Vancouver, BC, Canada.
Aliaksandr KarotkiSunnybrook Health Sciences Centre, Toronto, ON, Canada.
Alexander V LouieSunnybrook Health Sciences Centre, Toronto, ON, Canada.
Andrew WarnerVerspeeten Family Cancer Centre, London Health Sciences Centre, London, ON, Canada.
Jason VickressDepartment of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
X Melody QuDepartment of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
David A PalmaDepartment of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical demand for reirradiation is increasing; however, evidence for dose guidance to estimate normal tissue toxicity is lacking. The goal of the REPAIR trial is to determine the maximally tolerated dose (MTD) of reirradiation in the thorax, implemented by sequentially increasing the normal tissue recovery factors applied to previously delivered dose.

methodsThis multi-institution phase I dose-escalation study for patients undergoing thoracic reirradiation will use a time-to-event continual reassessment method (TITE-CRM). The MTD of reirradiation in this trial is represented by the recovery factor equation associated with a 35% or lower rate of Common Terminology Criteria for Adverse Events (CTCAE) grade 3–5 treatment-related toxicity occurring within 1 year of treatment. Accrual will start at level 1 (recovery factor = 10% at 6 months + 0.75% per month thereafter). Patients (n = 48) will be assigned to recovery factors using the TITE-CRM model. The model will use all available information from previously accrued patients to assign the highest dose with a predicted risk of grade 3–5 toxicity of 35% or less. Patients with recurrence, metastasis, or new primary malignancies in the thorax requiring radiation and who have previously received radiotherapy to the thorax, where reirradiation is expected to exceed the dose constraints used for de novo treatments, are eligible. DISCUSSION: This study will provide information on the safety of dose escalation for thoracic reirradiation using the concept of recovery after radiation.

trial registrationClinicaltrials.gov identifier: NCT06558175 (registration date August 14, 2024).

Indexed as

Lung NeoplasmsRe-IrradiationThoracic NeoplasmsClinical Trials, Phase I as TopicDose-Response Relationship, RadiationHumansMaximum Tolerated DoseMulticenter Studies as TopicNeoplasm Recurrence, LocalRadiotherapy DosageDose escalationEsophageal cancerLung cancerRadiotherapyReirradiationThoracic malignancy

Identifiers

PMID42026560
PMCPMC13244877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.